½Å ÀÌ½Ä ÈÄ Ç×ü ¸Å°³¼º °ÅºÎ¹ÝÀÀ ȯÀÚ¿¡¼­ Áö¿¬¼º ȸº¹À» º¸ÀÎ Ä¡·á 1¿¹
A Case of Delayed Recovery from Antibody-Mediated Rejection

´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 2È£ p.237 ~ p.241

Á¶ÇüÁø(Cho Hyung-Jin) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú
½ÅÀºÇý(Shin Eun-Hye) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú
¾ç¿µÁÖ(Yang Young-Joo) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú
Á¤Áö¿ø(Jung Ji-Won) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú
ÃÖ¿µ±Ç(Choi Young-Kwon) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú
¹Ú¼ö±æ(Park Su-Kil) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ³»°ú

Abstract

Ç×ü ¸Å°³¼º °ÅºÎ¹ÝÀÀÀº ÀÌ½Ä ½Å ±â´É»ó½Ç¿¡ Áß¿äÇÑ ¿øÀÎÀ¸·Î ÇöÀç±îÁö È®¸³µÈ Ä¡·á¹æ¹ýÀÌ ¾ø´Â »óÅÂÀÌ´Ù. Ç×ü ¸Å°³¼º °ÅºÎ¹ÝÀÀÀÇ ¿øÀÎÀ¸·Î »ý°¢µÇ´Â Á¦°øÀÚ Æ¯ÀÌ Ç×üÀÇ °æ¿ì ¸é¿ª¾ïÁ¦Á¦¸¦ Àß º¹¿ëÇÏÁö ¾Ê¾Æ¼­ Áö¿¬¼ºÀ¸·Î ¹ß»ýÇÏ´Â °æ¿ì°¡ ÀÖ¾î, Áö¼ÓÀûÀÎ ¸é¿ª¾ïÁ¦Á¦ º¹¿ëÀÇ ±³À°ÀÌ ÇÊ¿äÇÏ´Ù. Ç×ü ¸Å°³¼º °ÅºÎ¹ÝÀÀ¿¡ ÀÖ¾î ÃÖ±Ù Ä¡·á·Î µµÀÔµÈ bortezomib ´Üµ¶Ä¡·á·Î¼­ ȸº¹À» º¸ÀÌÁö ¾Ê¾Ò´ø Áõ·Ê¿¡¼­ rituximabÀ» Ãß°¡·Î Ä¡·áÇÏ¿© Áö¿¬¼º ȸº¹À» º¸ÀÎ Áõ·Ê¸¦ º¸°íÇϸç ÀϹÝÀûÀÎ Ä¡·á¹ýÀ¸·Îµµ ȸº¹µÇÁö ¾Ê´Â Ç×ü ¸Å°³¼º °ÅºÎ¹ÝÀÀ¿¡¼­ rituximab°ú bortezomibÀÇ º´ÇÕÄ¡·á¸¦ °í·ÁÇØ º¼ ¼ö ÀÖ°Ú°í Ãß°¡ÀûÀÎ ¿¬±¸°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.
Antibody-mediated rejection (ABMR) in kidney transplant recipients is mediated by donor-specific antibodies. It is the major cause of graft failure in noncompliant patients and is associated with reduced long-term graft survival. We present a case of delayed recovery of renal function despite aggressive therapy after acute ABMR. A 49-year-old male on triple-drug maintenance immunosuppression (prednisolone, cyclosporine, and azathioprine), who underwent cadaveric donor renal transplantation 14 years earlier, visited our clinic with a serum creatinine level (SCr) of 1.9 mg/dL. The kidney biopsy revealed acute ABMR with diffuse C4d immunopositivity. We started steroid pulse therapy and bortezomib with plasmapheresis. Nevertheless, the SCr increased. Consequently, antithymocyte globulin (ATG) and intravenous immunoglobulin were administered. The SCr increased further to 4.1 mg/dL. Therefore, we performed a second kidney biopsy, which showed no change. Finally, we used rituximab. Fortunately, the SCr decreased gradually and returned to baseline.

Å°¿öµå

½ÅÀåÀ̽Ä, °ÅºÎ¹ÝÀÀ
Kidney transplantation, Graft rejection, Medication adherence
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå